The aspirin metabolite, salicylate, inhibits 7,12-dimethylbenz[a] anthracene-DNA adduct formation in breast cancer cells

International Journal of Oncology

Volumn 28, Issue 5, 2006, Pages 1131-1140

  Abbadessa, Giuliana ^a   Spaccamiglio, Angela ^a   Sartori, Maria Luisa ^a   Nebbia, Carlo ^a   Dacasto, Mauro ^a   Di Carlo, Francesco ^a   Racca, Silvia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

7,12 dimethylbenzanthracene; Aspirin; Breast cancer cells; COX; CYP1A; DNA adducts

Indexed keywords

7,12 DIMETHYLBENZ(A)ANTHRACENE DNA ADDUCT; 7,12 DIMETHYLBENZ[A]ANTHRACENE; 7,12-DIMETHYLBENZ(A)ANTHRACENE-DNA ADDUCT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 1A1; DRUG DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; SALICYLIC ACID DERIVATIVE;

ANIMAL; ARTICLE; BREAST TUMOR; DNA ADDUCT; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HUMAN; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 CYP1A1; DNA ADDUCTS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; SALICYLATES;

EID: 33646830309     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.5.1131     Document Type: Article

References (75)

1. Sporn MB and Suh N: Chemoprevention of cancer. Carcinogenesis 21: 525-530, 2000.
2. Swede H, Mirand AL, Menezes RJ and Moysich KB: Association of regular aspirin use and breast cancer risk. Oncology 68: 40-47, 2005.
3. Schreinemachers DM and Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146, 1994.
4. Harris RE, Namboodiri KK and Farrar WB: Non-steroidal antiinflammatory drugs and breast cancer. Epidemiology 7: 203-205, 1996.
5. Harris RE, Kasbari S and Farrar WB: Prospective study of non-steroidal anti-inflammatory drugs and breast cancer. Oncol Rep 6: 71-73, 1999.
6. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF and Hanley JA: Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83: 112-120, 2000.
7. Cotterchio M, Kreiger N, Sloan M and Steingart A: Non-steroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10: 1213-1217, 2001.
8. Johnson TW, Anderson KE, Lazovich D and Folsom AR: Association of aspirin and non-steroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 11: 1586-1591, 2002. (Pubitemid 36020011)
9. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo Jl, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A, Women's Health Initiative: Breast cancer and non-steroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 63: 6096-6101, 2003.
10. Khuder SA and Mutgi AB: Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84: 1188-1192, 2001.
11. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ and Neugut AI: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291: 2433-2440, 2004.
12. Jang TJ, Jung HG, Jung KH and O MK: Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int J Exp Pathol 83: 173-182, 2002.
13. Lu S, Zhang X, Badawi AF, El-Sohemy A and Archer MC: Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett 184: 7-12, 2002.
14. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL and Harris RE: Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 21: 3425-3432, 2001.
15. Alshafie GA, Abou-Issa HM, Seibert K and Harris RE: Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 7: 1377-1381, 2000.
16. Harris RE, Alshafie GA, Abou-Issa H and Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101-2103, 2000.
17. McCormick DL, Madigan MJ and Moon RC: Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 45: 1803-1808, 1985.
18. Kubatka P, Ahlers I, Ahlersova E, Adamekova E, Luk P, Bojkova B and Markova M: Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. Cancer Lett 202: 131-136, 2003.
19. Kundu N and Fulton AM: Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62: 2343-2346, 2002.
20. Han EK, Arber N, Yamamoto H, Lim JT, Delohery T, Pamukcu R, Piazza GA, XingWQ and Weinstein IB: Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 48: 195-203, 1998.
21. Kundu N, Smyth MJ, Samsel L and Fulton AM: Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat 76: 57-64, 2002.
22. Oh KW, Qian T, Brenner DA and Lemasters JJ: Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicol Sci 73: 44-52, 2003.
23. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ and Mukherjee P: Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2: 632-642, 2004.
24. Prosperi JR, Mallery SR, Kigerl KA, Erfurt AA and Robertson FM: Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2. Prostaglandins Other Lipid Mediat 73: 249-264, 2004.
25. Fife RS, Stott B and Carr RE: Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro. Cancer Biol Ther 3: 228-232, 2004.
26. Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E and Bouchier-Hayes DJ: Cyclo-oxygenase inhibition reduces tumour growth and metastasis in anorthotopic model of breast cancer. Br J Cancer 87: 231-237, 2002.
27. Rozic JG, Chakraborty C and Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93: 497-506, 2001.
28. Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ and Pollak M: Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 316: 421-428, 2004.
29. Teh SH, Hill AK, Foley DA, McDermott EW, O'Higgins NJ and Young LS: COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. J Cell Biochem 91: 796-807, 2004.
30. Simeone AM, Li YJ, Broemeling LD, Johnson MM, Tuna M and Tari AM: Cyclooxygenase-2 is essential for HER2/neu to suppress N-(4-hydroxyphenyl) retinamide apoptotic effects in breast cancer cells. Cancer Res 64: 1224-1228, 2004.
31. Timoshenko AV, Xu G, Chakrabarti S, Lala PK and Chakraborty C: Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 289: 265-274, 2003.
32. Miller EC and Miller JA: Mechanisms of chemical carcinogenesis. Cancer 47: 1055-1064, 1981.
33. Williams JA and Phillips DH: Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 60: 4667-4677, 2000.
34. Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455-460, 1998.
35. Singletary KW, Nelshoppen JM, Scardefield S and Wallig M: Inhibition by butylated hydroxytoluene and its oxidative metabolites of DMBA-induced mammary tumorigenesis and of mammary DMBA-DNA adduct formation in vivo in the female rat. Food Chem Toxicol 30: 455-465, 1992.
36. Singletary KW, MacDonald C and Wallig M: Inhibition by rosemary and carnosol of 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation. Cancer Lett 104: 43-48, 1996.
37. Singletary KW, MacDonald C, Wallig M and Fisher C: Inhibition of 7,12- dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett 103: 137-141, 1996.
38. Singletary KW, MacDonald C and Wallig M: The plasticizer benzyl butyl phthalate (BBP) inhibits 7,12-dimethylbenz[a] anthracene (DMBA)-induced rat mammary DNA adduct formation and tumorigenesis. Carcinogenesis 18: 1669-1673, 1997.
39. Liu J, Gilbert K, Parker HM, Haschek WM and Milner JA: Inhibition of 7,12-dimethylbenz(a)anthracene-induced mammary tumors and DNA adducts by dietary selenite. Cancer Res 51: 4613-4617, 1991.
40. El-Bayoumi K, Chae YH, Upadhyaya P, Meschter C, Cohen LA and Reddy BS: Inhibition of 7-12-dimethylbenz[a]anthracene (DMBA)-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound, 1,4-phenyl-enebis(methylene) selenocyanate. Cancer Res 52: 2402-2407, 1992.
41. Das SK, Jia TZ, Bandyopadhyay AM and Banerjee MR: β-carotene- mediated inhibition of a DNA adduct induced by 7-12- dimethylbenz(a)anthracene and 7-hydroxymethyl-12-methylbenz(a)anthracene in mouse mammary gland in vitro. Eur J Cancer 28: 1124-1129, 1992.
42. Ip C, Vadhanavikit S and Ganther H: Cancer chemoprevention by aliphatic selenocyanates: effect of chain length on inhibition of mammary tumors and DMBA adducts. Carcinogenesis 16: 35-38, 1995.
43. Amagase H, Schaffer EM and Milner JA: Dietary components modify the ability of garlic to suppress 7,12-dimethylbenz(a) anthracene-induced mammary DNA adducts. J Nutr 126: 817-824, 1996.
44. Schaffer EM, Liu JZ and Milner JA: Garlic powder and allyl sulfur compounds enhance the ability of dietary selenite to inhibit 7,12-dimethylbenz[a]anthracene-induced mammary DNA adducts. Nutr Cancer 27: 162-168, 1997.
45. Ciolino HP and Yeh GC: The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br J Cancer 79: 1340-1346, 1999.
46. Ciolino HP, MacDonald CJ and Yeh GC: Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one. Cancer Res 62: 3685-3690, 2002.
47. Larsen MC, Angus WG, Brake PB, Elpton SE, Sukow KA and Jefcoate CR: Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. Cancer Res 58: 2366-2374, 1998.
48. Mahadevan B, Keshava C, Musafia-Jeknic T, Pecaj A, Weston A and Baird WM: Altered gene expression patterns in MCF-7 cells induced by the urban dust particulate complex mixture standard reference material 1649a. Cancer Res 65: 1251-1258, 2005.
49. Mahadevan B, Parsons H, Musafia T, Sharma AK, Amin S, Pereira C and Baird WM: Effect of artificial mixtures of environmental polycyclic aromatic hydrocarbons present in coal tar, urban dust, and diesel exhaust particulates on MCF-7 cells in culture. Environ Mol Mutagen 44: 99-107, 2004.
50. Ghezzo F, Cesano L, Mognetti B, Pesce E, Pirro E, Corvetti G, Berta GN, Zingaro B and Di Carlo F: Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration. Int J Oncol 26: 697-702, 2005.
51. Yamashita J, Horiuchi S, Shigaki N, Fujino N and Akagi M: Estrogen-dependent plasminogen activator in 7,12-dimethylbenz-[a]anthracene- induced rat mammary tumors in vivo and in vitro. Gann 75: 681-689, 1984.
52. Moore CJ, Tricomi WA and Gould MN: Interspecies comparison of polycyclic aromatic hydrocarbon metabolism in human and rat mammary epithelial cells. Cancer Res 46: 4946-4952, 1986.
53. Nebert DW: Genetic differences in the microsomal electron transport: the Ah locus. In: Methods in Enzymology. Fleischer S and Packer L (eds). New York Academic Press, pp227-240, 1978.
54. Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988.
55. Lowry OH, Rosebrough NJ, Farr AL and Randal RJ: Protein measurement with Folin phenol reagent. J Biol Chem 193: 265, 1951.
56. Pham H, Banerjee T and Ziboh VA: Suppression of cyclooxygenase-2 overexpression by 15s-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells. Int J Cancer 111: 192-197, 2004.
57. Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye-binding. Anal Biochem 72: 248-254, 1976.
58. Twentyman PR and Luscombe M: A study of some variables in a tetrazolium dye-(MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285, 1987.
59. Novelli F, Giovarelli M, Reber-Liske R, Virgallita G, Garotta G and Forni G: Blockade of physiologically secreted IFN-γ inhibits human T lymphocyte and natural killer cell activation. J Immunol 147: 1445-1452, 1991.
60. Korzeniewsky C and Callewaert DM: An enzyme release assay for natural cytotoxicity. J Immunol Methods 64: 313-320, 1983.
61. Maniatis T, Fritsch EF and Sambrook J: Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory, pp157-161, 1982.
62. Dipple A, Moschel RC and Bigger CAH: Polynuclear aromatic carcinogens. In: Chemical Carcinogens. Searle CE (ed). ACS Monographs American Chemical Society, Washington, DC, pp41-174, 1984.
63. Grilli M, Pizzi M, Memo M and Spano P: Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274: 1383-1385, 1996.
64. Yin M-J, Yamamoto Y and Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396: 77-80, 1998.
65. Rowlands JC, He L, Hakkak R, Ronis MJ and Badger TM: Soy and whey proteins downregulate DMBA-induced liver and mammary gland CYP1 expression in female rats. J Nutr 131: 3281-3287, 2001.
66. Buchmann A, Kuhlmann W, Schwarz M, Kunz W, Wolf CR, Moll E, Friedberg T and Oesch F: Regulation and expression of four cytochrome P-450 isoenzymes, NADPH-cytochrome P-450 reductase, the glutathione transferases B and C and microsomal epoxide hydrolase in preneoplastic and neoplastic lesions in rat liver. Carcinogenesis 6: 513-521, 1985.
67. Roomi MW, Ho RK, Sarma DS and Farber E: A common biochemical pattern in preneoplastic hepatocyte nodules generated in four different models in the rat. Cancer Res 45: 564-571, 1985.
68. Stout DL and Becker FF: Xenobiotic metabolizing enzymes in genetically and chemically initiated mouse liver tumors. Cancer Res 46: 2693-2696, 1986.
69. Din FV, Dunlop MG and Stark LA: Evidence for colorectal cancer cell specificity of aspirin effects on NF kappaB signalling and apoptosis. Br J Cancer 91: 381-388, 2004.
70. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G and Harris RE: Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 122: 165-175, 1998.
71. Smith WL, De Witt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
72. Wang D and Dubois RN: Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 31: 64-73, 2004.
73. Sotiriou C, Lacroix M, Lagneaux L, Berchem G and Body JJ: The aspirin metabolite salicylate inhibits breast cancer cells' growth and their synthesis of the osteolytic cytokines interleukins-6 and -11. Anticancer Res 19: 2997-3006, 1999.
74. Planchon P, Veber N, Magnien V, Prevost G, Starzec AB and Israel L: Evidence for separate mechanisms of antiproliferative action of indomethacin and prostaglandin on MCF-7 breast cancer cells. Life Sci 57: 1233-1240, 1995.
75. Noguchi M, Earashi M, Minami M, Miyazaki I, Tanaka M and Sasaki T: Effects of piroxicam and esculetin on the MDA-MB-231 human breast cancer cell line. Prostagland Leukotr Essent Fatty Acids 53: 325-329, 1995.